title: [Prevalence and treatment of anemia in critically ill patients].
abstract: Anemia is a common condition among medical and surgical patients admitted to the intensive care unit (ICU) and generally has a multifactorial origin. In order to avoid the deleterious effects of anemia, 40% of ICU patients receive allogenic blood transfusion (ABT). This figure increases up to 70% if the ICU stay is longer than 7 days. However, ABT is associated with a dose-dependent increase in morbidity and mortality. In contrast, the administration of exogenous erythropoietin plus iron supplements, especially iv iron, improves anemia and reduces ABT requirements, although it does not reduce mortality. To ascertain whether treatment of anemia in the critically ill with exogenous erythropoietin and iron might improve outcomes and to optimize drug administration schedules and dosage, further studies with sufficient statistical power and adequate follow-up are warranted.
authors.affiliation: Medicina Transfusional, Facultad de Medicina, Málaga, and Servicio de Cuidados Intensivos y Urgencias, Hospital Universitario Virgen del Rocío, Sevilla, Spain. mmunoz@uma.es
authors.forename: M
authors.initials: M
authors.lastname: Muñoz
authors.forename: S R
authors.initials: SR
authors.lastname: Leal-Noval
authors.forename: J A
authors.initials: JA
authors.lastname: García-Erce
authors.forename: E
authors.initials: E
authors.lastname: Naveira
mesh_terms: D000740:Anemia / Q000453:epidemiology* / Q000209:etiology / Q000628:therapy*; D001803:Blood Transfusion; D016638:Critical Illness; D004920:Erythropoiesis; D004921:Erythropoietin / Q000627:therapeutic use; D006801:Humans; D007275:Injections, Intravenous; D007501:Iron / Q000008:administration & dosage; D015995:Prevalence; D011994:Recombinant Proteins
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin; D007501:Iron